Evaxion Biotech has entered into a binding agreement for a financing of up to 20 million USD with Negma Group Investment.
“We are pleased to be able to establish a flexible financing vehicle with Negma Group. The ability to attract such an experienced investor is a tribute to Evaxion’s AI technology and pipeline progress,” says Per Norlén, Chief Executive Officer of Evaxion.
“We are proud to partner with Evaxion as they advance the next-generation personalized cancer vaccines to develop superior immunotherapies for patients in need.”
Financing is available in tranches of up to USD 700,000 over a period of 36 months. Executing individual tranches and the timing of such tranches is at the discretion of Evaxion subject to certain terms and conditions. The convertible bonds carry a zero coupon and will be issued at a subscription price corresponding to their par value. The conversion price will be determined as 83.5% of the second lowest closing volume weighted average share price (VWAP) of at least 8 trading days immediately preceding the issuance of each conversion request by Negma.
“We are excited to collaborate with Evaxion. At Negma Group, we invest in people who bring forth forward-thinking, data-driven solutions. We have been very impressed by both the scientific innovation and expertise of the Evaxion team, and the clinical data presented to date for the programs in oncology. We are proud to partner with Evaxion as they advance the next-generation personalized cancer vaccines to develop superior immunotherapies for patients in need,” says Sophie Villedieu, Equity Capital Market of Negma Group.
Sufficient financing to fund its planned activities into Q4 2024
The financing commitments are intended to cover the company’s working capital needs, including the ongoing clinical phase 2 trial of EVX-01, and the advancement of EVX-03 towards the initiation of a Phase 1 clinical trial. If Evaxion fully utilizes the convertible note program, the company will have sufficient financing to fund its planned activities into Q4 2024.
Evaxion plans to announce the interim results of the clinical Phase 2 study with EVX-01 in patients with metastatic melanoma in Q4 2023, a program where promising Phase 1/2a data were presented at ASCO in June 2023. In addition, the Company plans to initiate a Phase 1 clinical trial with EVX-03 in patients with lung cancer and other solid tumors. EVX-03 is based on the use of Evaxion’s AI-technology and novel ObsERV platform, which enables the company to identify new patient-specific tumor targets called ERVs to enhance the efficacy of its personalized cancer vaccines, with potential to broaden the utility to patients unresponsive to current immunotherapies.
Photo of Per Norlén, CEO, Evaxion